Please wait while the transcript is being prepared...
0:00
The topic of antibody
drug conjugates,
ADCs, will be explored through
the concept, structure,
and mechanism of ADCs as a
targeted cancer therapy,
highlighting their three
essential components,
monoclonal antibody,
chemical linker, and
cytotoxic payload.
We will examine how
ADCs selectively
deliver potent drugs
to cancer cells while
sparing healthy
tissue and discuss
their clinical application and
benefits over
conventional treatments.
Finally, we will address current
challenges in ADC development,
such as optimizing stability,
reducing off target effects,
and improving
manufacturing, as well as
innovations advancing their
use in personalized medicine.
Antibody drug conjugates or
ADCs are a novel class of
targeted cancer therapist,
merging the specificity
of monoclonal
antibodies with the
potent toxicity
of small molecule drugs.
ADCs embody Paul Ehrlich's
magic bullet idea,
delivering strong drugs to
tumor cells while
sparing healthy tissue.
Each ADC has three parts,
a monoclonal antibody,
a chemical linker, and a
cytotoxic payload or warhead.
ADCs have transformed
personalized cancer therapy,
offering hope for patients
with resistant cancers.
Let's briefly explore the three
main components of an ADC.
The antibody provides
specificity,
targeting antigens
highly expressed on
tumor cells while
sparing healthy tissue.
Target selection is critical.
The antigen must be abundant
on cancer cells and
minimal on normal cells to
